Study of Octanorm Subcutaneous IG in Patients With PID

O

Octapharma

Status and phase

Completed
Phase 3

Conditions

Primary Immune Deficiency Disorder

Treatments

Biological: octanorm 16.5%

Study type

Interventional

Funder types

Industry

Identifiers

NCT01888484
SCGAM-01

Details and patient eligibility

About

This is an open-label phase III study with a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main goals of the study are to assess the efficacy of octanorm in preventing serious bacterial infections (SBI) compared with historical control data and to evaluate the pharmacokinetic (PK) characteristics of octanorm.

Enrollment

75 patients

Sex

All

Ages

2 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age of at least 2 years up to and including 75 years.
  • Confirmed diagnosis of PI as defined by the ESID and PAGID and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PI should be recorded.
  • Patients with at least 6 infusions on regular treatment with any IVIG, there of a minimum of the last 2 months on the same product prior to entering the study. Constant IVIG dose between 200 and 800 mg/kg body weight (±20% of the mean dose for the last 6 infusions).
  • Availability of the IgG trough levels of 2 previous IVIG infusions before enrollment, and maintenance of greater than or equal to 5.0 g/L in the trough levels of these 2 previous infusions.
  • Negative result on a pregnancy test (HCG-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study.
  • For adult patients: freely given written informed consent. For minor patients: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with the applicable regulatory requirements.
  • Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

Exclusion criteria

  • Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and during the screening period.
  • Known history of adverse reactions to IgA in other products.
  • Patients with body mass index ≥40 kg/m2.
  • Exposure to blood or any blood product or plasma derivatives, other than IVIG treatment for PID, within the past 3 months prior to the first infusion of octanorm.
  • Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product (such as Polysorbate 80).
  • Requirement of any routine premedication for IgG administration.
  • History of malignancies of lymphoid cells and immunodeficiency with lymphoma.
  • Severe liver function impairment (ALAT 3 times above upper limit of normal).
  • Known protein-losing enteropathies or proteinuria.
  • Presence of renal function impairment (creatinine greater than 120 uM/L), or creatinine greater than 1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
  • Treatment with oral or parenteral steroids for greater than or equal to 30 days or when given intermittently or as bolus at daily doses greater than or equal to 0.15 mg/kg.
  • Treatment with immunosuppressive or immunomodulatory drugs.
  • Live viral vaccination (such as measles, rubella, mumps and varicella) within the last 2 months prior to first infusion of octanorm.
  • Treatment with any investigational medicinal product within 3 months prior to first infusion of octanorm.
  • Presence of any condition, that is likely to interfere with the evaluation of study medication or satisfactory conduct of the trial.
  • Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to first infusion of octanorm.
  • Known or suspected HIV, HCV, or HBV infection.
  • Pregnant or nursing women.
  • Planned pregnancy during the course of the study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

75 participants in 1 patient group

Octanorm 16.5%
Experimental group
Description:
octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
Treatment:
Biological: octanorm 16.5%

Trial documents
2

Trial contacts and locations

24

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems